Kim, R. D., Hollebecque, A., Ryan, K., Schram, A. M. (2026). A phase 2, open-label, single-arm study of lirafugratinib in patients with previously treated, unresectable, locally advanced, or metastatic solid tumors (excluding cholangiocarcinoma) with FGFR2 fusion or rearrangement.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps4251